Literature DB >> 15728293

Independent accumulations of tau and amyloid beta-protein in the human entorhinal cortex.

T Katsuno1, M Morishima-Kawashima, Y Saito, H Yamanouchi, S Ishiura, S Murayama, Y Ihara.   

Abstract

BACKGROUND: Previous studies have repeatedly described that neurofibrillary tangles arise earlier than senile plaques (SPs) in the entorhinal cortex, but one study suggested that SPs, if present, enhance the former lesions. All of these studies were performed at the histologic or immunocytochemical level, which may not accurately reflect the actual levels of amyloid beta-protein (Abeta) and tau.
OBJECTIVE: To determine whether there is significant interaction between Abeta and tau in the human entorhinal cortex with regard to the Braak stage.
METHODS: Biochemical studies were conducted on 50 brains from elderly people, who were mainly at Braak stages I to III. All the cases were examined neuropathologically and staged according to Braak and Braak. A small piece of brain tissue for each case was dissected from the anterior portion of the right entorhinal cortex. The amounts of tau and Abeta in the insoluble fraction of the tissue were quantified using western blotting.
RESULTS: The levels of tau and possibly Abeta42 in the entorhinal cortex appeared to rise steeply at approximately age 75. The levels of insoluble tau increased as the Braak stage increased from I to II; however, it had a tendency to remain between stages II and III. The levels of Abeta42 showed a small increase, whereas those of Abeta40 increased continuously as the Braak stage advanced. In contrast, the extent of Abeta42 accumulation increased with increasing Braak stage for SPs. There was no significant correlation between the levels of insoluble tau and Abeta42 in the entorhinal cortex. Even if Abeta did not accumulate to significant extents, substantial accumulation of insoluble tau occurred.
CONCLUSION: Accumulations of tau and amyloid beta-protein occur independently in the human entorhinal cortex.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15728293     DOI: 10.1212/01.WNL.0000151958.79884.86

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  8 in total

1.  Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model.

Authors:  Kunie Ando; Karelle Leroy; Céline Héraud; Zehra Yilmaz; Michèle Authelet; Valèrie Suain; Robert De Decker; Jean-Pierre Brion
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 2.  JNK: a stress-activated protein kinase therapeutic strategies and involvement in Alzheimer's and various neurodegenerative abnormalities.

Authors:  Sidharth Mehan; Harikesh Meena; Deepak Sharma; Rameshwar Sankhla
Journal:  J Mol Neurosci       Date:  2010-09-28       Impact factor: 3.444

3.  Challenges in the conduct of disease-modifying trials in AD: practical experience from a phase 2 trial of Tau-aggregation inhibitor therapy.

Authors:  C Wischik; R Staff
Journal:  J Nutr Health Aging       Date:  2009-04       Impact factor: 4.075

Review 4.  Alzheimer 100--highlights in the history of Alzheimer research.

Authors:  K A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2006-10-13       Impact factor: 3.575

5.  The presubiculum links incipient amyloid and tau pathology to memory function in older persons.

Authors:  Heidi I L Jacobs; Jean C Augustinack; Aaron P Schultz; Bernard J Hanseeuw; Joseph Locascio; Rebecca E Amariglio; Kathryn V Papp; Dorene M Rentz; Reisa A Sperling; Keith A Johnson
Journal:  Neurology       Date:  2020-04-09       Impact factor: 9.910

6.  P301S mutant human tau transgenic mice manifest early symptoms of human tauopathies with dementia and altered sensorimotor gating.

Authors:  Hiroki Takeuchi; Michiyo Iba; Haruhisa Inoue; Makoto Higuchi; Keizo Takao; Kayoko Tsukita; Yoshiko Karatsu; Yumiko Iwamoto; Tsuyoshi Miyakawa; Tetsuya Suhara; John Q Trojanowski; Virginia M-Y Lee; Ryosuke Takahashi
Journal:  PLoS One       Date:  2011-06-15       Impact factor: 3.240

Review 7.  Targeting Renin-Angiotensin System Against Alzheimer's Disease.

Authors:  Abadi Kahsu Gebre; Birhanetensay Masresha Altaye; Tesfay Mehari Atey; Kald Beshir Tuem; Derbew Fikadu Berhe
Journal:  Front Pharmacol       Date:  2018-04-30       Impact factor: 5.810

8.  Sex modifies APOE ε4 dose effect on brain tau deposition in cognitively impaired individuals.

Authors:  Shaozhen Yan; Chaojie Zheng; Manish D Paranjpe; Yanxiao Li; Weihua Li; Xiuying Wang; Tammie L S Benzinger; Jie Lu; Yun Zhou
Journal:  Brain       Date:  2021-11-29       Impact factor: 13.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.